

1 SENATE CORPORATIONS AND TRANSPORTATION COMMITTEE SUBSTITUTE FOR
2 SENATE BILL 394

3 **54TH LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2019**

4
5
6
7
8
9
10 AN ACT

11 RELATING TO PHARMACIES; PROVIDING FOR CHANGES TO THE PHARMACY
12 AUDIT PROCESS; EXCEPTING CERTAIN AUDIT FINDINGS FROM FORMING
13 THE BASIS FOR RECOUPMENT; ADDING A PHARMACY BENEFITS MANAGER OR
14 ITS SUBCONTRACTOR AS AN AUDITING ENTITY.

15
16 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

17 SECTION 1. Section 61-11-18.2 NMSA 1978 (being Laws 2007,
18 Chapter 15, Section 1) is amended to read:

19 "61-11-18.2. AUDIT OF PHARMACY RECORDS.--

20 [~~A. As used in this section, "entity" means a~~
21 ~~managed care company, insurance company, third-party payor or~~
22 ~~the representative of the managed care company, insurance~~
23 ~~company or third-party payor.~~

24 ~~B.]~~ A. An audit of the records of a pharmacy by an
25 entity shall be conducted in accordance with the following

.213892.1

underscored material = new
[bracketed material] = delete

1 criteria:

2 (1) the entity conducting the initial on-site
3 audit shall give the pharmacy notice at least two weeks prior
4 to conducting the initial on-site audit for each audit cycle;

5 (2) an audit that involves clinical or
6 professional judgment shall be conducted by or in consultation
7 with a pharmacist;

8 (3) a clerical or [~~record-keeping~~]
9 recordkeeping error, regarding a required document or record,
10 shall not necessarily constitute fraud, [~~but such a claim~~] and
11 that error:

12 (a) [~~may be subject to recoupment~~] shall
13 not be the basis for recoupment unless the error results in
14 overpayment to the pharmacy, and any amount to be charged back
15 or recouped due to overpayment shall not exceed the amount the
16 pharmacy was overpaid; and

17 (b) shall not be subject to criminal
18 penalties without proof of intent to commit fraud;

19 (4) a pharmacy may use the records of a
20 hospital, physician or other authorized practitioner of the
21 healing arts for drugs or medicinal supplies written or
22 transmitted by any means of communication for purposes of
23 validating the pharmacy record with respect to orders or
24 refills of a dangerous drug or controlled substance;

25 (5) a finding of an overpayment or

1 underpayment shall ~~[not be a projection based on the number of~~
2 ~~patients served having a similar diagnosis or on the number of~~
3 ~~similar orders or refills for similar drugs and recoupment of~~
4 ~~claims shall]~~ be based on the actual overpayment or
5 underpayment ~~[unless the entity demonstrates a statistically~~
6 ~~justifiable method of projection or the projection for~~
7 ~~overpayment or underpayment is part of a settlement as agreed~~
8 ~~to by the pharmacy]~~ of a specific individual claim;

9 (6) each pharmacy shall be audited under the
10 same standards and parameters as other similarly situated
11 pharmacies audited by the entity;

12 (7) a pharmacy shall be allowed at least
13 twenty-one business days, with reasonable extensions allowed,
14 following receipt of the preliminary audit report in which to
15 produce documentation to address any discrepancy found during
16 an audit;

17 (8) the period covered by an audit shall not
18 exceed two years ~~[unless otherwise provided by contractual~~
19 ~~agreement]~~ from the date the claim was submitted to or
20 adjudicated by an entity, ~~[or]~~ unless it conflicts with state
21 or federal law;

22 (9) an audit shall not be initiated or
23 scheduled during the first five calendar days of a month ~~[due~~
24 ~~to the high volume of prescriptions filled during that time~~
25 ~~unless otherwise consented to by the pharmacy];~~

.213892.1

1 (10) the preliminary audit report shall be
2 delivered to the pharmacy within one hundred twenty days, with
3 reasonable extensions allowed, after conclusion of the audit,
4 and the final report shall be delivered to the pharmacy within
5 six months after receipt of the preliminary audit report or
6 final appeal, as provided for in Subsection [E] B of this
7 section, whichever is later;

8 ~~[(11) the audit criteria set forth in this~~
9 ~~subsection shall apply only to audits of claims submitted for~~
10 ~~payment after July 1, 2007; and~~

11 ~~(12)]~~ (11) notwithstanding any other provision
12 in this ~~[subsection]~~ section, the entity conducting the audit
13 shall not use the accounting practice of extrapolation in
14 calculating recoupments or penalties for audits;

15 (12) the auditing entity conducting a pharmacy
16 audit shall not compensate an employee or contractor with which
17 an auditing entity contracts to conduct a pharmacy audit based
18 on the amount claimed or the actual amount recouped from the
19 pharmacy being audited;

20 (13) an entity shall not charge a fee for
21 conducting an on-site or a desk audit unless there is a finding
22 of actual fraud;

23 (14) as a result of an audit finding, a
24 pharmacist or pharmacy may resubmit a claim to correct clerical
25 or recordkeeping errors;

1 (15) the requirements for a valid prescription
2 or a pharmacy benefits manager's required operational standards
3 for pharmacies shall not be more stringent than federal or
4 state requirements;

5 (16) with notice to the prescriber, a pharmacy
6 or pharmacist may satisfy state and federal requirements for a
7 valid prescription by affixing or writing additional
8 information on the front or back of a prescription or if the
9 required information is electronically recorded on a patient's
10 profile and is readily retrievable;

11 (17) the days' supply for unit-of-use items,
12 such as topicals, drops, vials and inhalants, shall not be
13 limited beyond manufacturer recommendations;

14 (18) if the only commercially available
15 package size exceeds an entity's maximum days' supply, the
16 dispensing of such package size must be accepted by the entity
17 and shall not be the basis for recoupment;

18 (19) if the only commercially available
19 package size exceeds an entity's maximum days' supply and the
20 entity accepts the refill of such prescription, the entity
21 shall not recoup such claim as an early refill; and

22 (20) the failure of a pharmacy to collect a
23 copayment shall not be the basis for recoupment if the pharmacy
24 provides documentation of billing of the claim and makes a
25 reasonable attempt to collect the copayment.

.213892.1

1 ~~[G-]~~ B. Recoupment of any disputed funds shall
2 occur after final internal disposition of the audit, including
3 the appeals process set forth in Subsection ~~[D]~~ C of this
4 section. Should the identified discrepancy for an individual
5 audit exceed twenty-five thousand dollars (\$25,000), future
6 payments to the pharmacy may be withheld pending finalization
7 of the audit.

8 ~~[D-]~~ C. Each entity conducting an audit shall
9 establish an appeals process under which a pharmacy may appeal
10 an unfavorable preliminary audit report to the entity. If,
11 following the appeal, the entity finds that an unfavorable
12 audit report or any portion of the audit is unsubstantiated,
13 the entity shall dismiss the audit report or the
14 unsubstantiated portion of the report of the audit without the
15 necessity of any further proceedings.

16 ~~[E-]~~ D. This section does not apply to any
17 investigative audit that involves probable or potential fraud,
18 waste, abuse or willful misrepresentation.

19 E. In a wholesale invoice audit conducted by an
20 entity:

21 (1) an entity shall not audit the claims of
22 another entity;

23 (2) the following shall not form the basis for
24 recoupment:

25 (a) the national drug code for the

.213892.1

1 dispensed drug is in a quantity that is a sub-unit or multiple
2 of the purchased drug as reflected on a supporting wholesale
3 invoice;

4 (b) the correct quantity dispensed is
5 reflected on the audited pharmacy claim; or

6 (c) the drug dispensed by the pharmacy
7 on an audited pharmacy claim is identical to the strength and
8 dosage form of the drug purchased;

9 (3) the entity shall accept as evidence:

10 (a) supplier invoices issued prior to
11 the date of dispensing the drug underlying the audited claim;

12 (b) invoices from any supplier
13 authorized by law to transfer ownership of the drug acquired by
14 the audited pharmacy;

15 (c) copies of supplier invoices in the
16 possession of the audited pharmacy; and

17 (d) reports required by any state board
18 or agency; and

19 (4) within five business days of request by
20 the audited pharmacy, the entity shall provide supporting
21 documentation provided to the entity by the audited pharmacy's
22 suppliers.

23 F. The provisions of this section shall not be
24 waived, voided or nullified by contract.

25 G. As used in this section:

.213892.1

